EURASIAN PATENT OFFICE

EURASIAN PHARMACEUTICAL REGISTER

WIPO, SCP 37 session
Geneva, November 3-7, 2025

Aurelia Ceban
Deputy Director,
Examination Department
EAPO

EURASIAN PATENT ORGANIZATON (EAPO)



International Intergovernmental Organization

Founded in 1994 in accordance with the Eurasian Patent Convention (EAPC) to create regional system for inventions' protection based on common Eurasian patent

Regional patents for:

- Inventions
- Industrial designs

USERS FROM MORE THAN

130

COUNTRIES

Eurasian Patent Office is an executive body that administers the Eurasian patent system

EURASIAN PHARMACEUTICAL REGISTER

INFORMATION RETRIEVAL RESOURCE

PUBLICLY ACCESSIBLE

Searchable database on Eurasian and EAPC Member States' national patents related to active pharmaceutical ingredients having INN

- Formed and maintained by EAPO in electronic form on EAPO's website with free access
- Systematized on INN

Useful for a large circle of interested parties, involved in research, manufacturing, drug approval and drug marketing on territories of EAPO Member States

EVOLUTION

March 2021

- The purpose – to provide information on API-related Eurasian patents

July 2022

- Enlarged scope
- ➢ Includes Eurasian patents and EAPC Member States' national patents

December 2023

- ➢ The legal status of the EA PharmRegister was determined
- ➢ Regulations on Eurasian Pharmaceutical Register are adopted by the Administrative Council of the EAPO on December 7, 2023

KEY CHARACTERISTICS

Principles of formation and maintenance

- credibility and relevance of the information
- transparency and accessibility of the information
- free access
- continuity and uninterrupted functioning
- compliance of the information in the Pharmaceutical Register with the Eurasian patent Register and national patent Registers of EAPO Member States

The legal status of information included in the Pharmaceutical Register is determined as

- credible
- up-to-date
- systematized

ELIGIBLE PATENTS

Patents related to active pharmaceutical ingredients (API)

- Pharmacologically active products
  - chemical compounds, incl. Markush claims
  - biotechnological products (antibodies)
  - formulations of API
  - combinations of API
- Process of API production
- Medical uses of API





CONTENTS OF EURASIAN PHARMACEUTICAL REGISTER

- Eurasian and national patents grouped under INN / combination of INNs
- Legal status of patents in 8 EAPO Member States
  - statutory date of patent term expiration
  - In force / not in force for each Member State
  - direct link to Eurasian and national Patent Registers for full history on legal status
- Patent term extension in EAPO Member States
- Information on market authorizations (drug registrations) in EAPO Member States
- Registered licenses in EAPO Member States
- Information on compulsory licenses issued on the territory of EAPO Member States

INCLUSION OF INFORMATION IN THE PHARMACEUTICAL REGISTER

❑ Eurasian patents

- upon request of patent holder
- by EAPO on basis of patent term extensions

❑ National patents

- upon request of patent holder

Request of patent holder

- No charge (for EA patents)
- Information proving the link between claims and INN
- Copies of market authorizations (if any)
- Information on licensing agreements
- Translation of claims into the Russian language (for national patents)

KEEPING THE PHARM REGISTER

- Patents are entered only on basis of conformity examination of claimed subject-matter and INN
  - performed by EAPO's examiners skilled in the field
- Removing patents (inactive status)
  - expiration of statutory patent term
  - lapse in all member states / surrender of patent
  - invalidation in all Member States
  - upon a patent holder request
  - administrative error
- Amendments
  - upon request of patent holder or market authorization holder
- All entries / data may be revised under third-party observations

EXTRACTS FROM THE PHARMREGISTER

- Extracts from PharmRegister are provided by EAPO
  - to any person upon request
  - upon the request of judicial and other competent authorities of Member States

- contain information on the compliance of the patented subject matter with a specific INN or a combination of INN, indicating the claims under the Eurasian or, respectively, national patent protecting the API

- certifies the protection of API-related inventions by Eurasian or national patent on the territory of the respective Member State

CONTENTS OF THE PHARM REGISTER

As on 1 November 2025:

- 456 patents
  - 395 Eurasian patents
  - 61 national patents
- 271 INN (combination INN)
- more than 400 registered medicines

SEARCHING THE PHARMA REGISTER

Searchable fields:

- INN / combination of INNs (RU, EN)
- patent number
- patent owner (RU, EN)
- title of Invention (RU, EN)
- type of patent (Eurasian, national)
- territory of Member State(s)



EURASIAN PHARMACEUTICAL REGISTRY

Eurasian patent no. EA 035999

(11) Eurasian Patent Number	035999
(22) Filling Date	2007.06.21
(73) Patent Owner	АСТРАЗЕНЕКА АБ (SE) ASTRAZENECA AB (SE)
(54) Title of the Invention	КРИСТАЛЛИЧЕСКИЕ СОЛЬВАТЫ И КОМПЛЕКСЫ ПРОИЗВОДНЫХ (1S)-1,5-АНГИДРО-1-С-(3-((ФЕНИЛ)МЕТИЛ)ФЕНИЛ)-D-ГЛЮЦИТОЛА С АМИНОКИСЛОТАМИ В КАЧЕСТВЕ ИНГИБИТОРОВ SGLT2 ДЛЯ ЛЕЧЕНИЯ ДИАБЕТА CRYSTALLINE SOLVATES AND COMPLEXES OF (1S)-1,5-ANHYDRO-1-C-(3-((PHENYL)METHYL)PHENYL)-D-GLUCITOL DERIVATIVES WITH AMINO ACIDS AS SGLT2 INHIBITORS FOR THE TREATMENT OF DIABETES
Validity date (based on 20-year validity term)	2027.06.21
International nonproprietary name (combination)	ДАПАГЛИФЛОЗИН / DAPAGLIFLOZIN

Patent validity		Patent term extension
AM	Not valid from 2021.06.22	
AZ	Not valid from 2021.06.22	
BY	Valid until 2032.06.21	Extended for Форсига (Дапаглифлозин) until 2032.06.21
KG	Not valid from 2021.06.22	
KZ	Valid until 2032.06.21	Extended for Форсига (Дапаглифлозин) until 2032.06.21
MD	Not valid from 2021.06.22	
RU	Valid until 2029.08.21	Extended for Форсига (Дапаглифлозин) until 2029.08.21
TJ	Not valid from 2021.06.22	
TM	Not valid from 2021.06.22	

Issued registration certificates

Country	Registration certificate number and date of issue	Trade name of the medicinal product (INN)	Registration certificate holder
BY	10968/21 2021.06.21	Форсига (ДАПАГЛИФЛОЗИН)	АстраЗенека АБ (SE)
RU	ЛП-002596 2014.08.21	Форсига (Дапаглифлозин)	Бристол-Майерс Сквибб Компани (USA) (null)
KZ	РК-ЛС-5№023471 2018.01.15	Форсига (Дапаглифлозин)	АстраЗенека АБ (SE)

Rights of use

EURASIAN PHARMACEUTICAL REGISTRY

EAPO

INN (combination)
REGORAFENIB

Patent Number
Enter patent number

Patent Owner(s)
Enter patent owner information

Title of the Invention
Enter the title of the invention

Patent status
Active

EA AM AZ BY KG KZ RU TJ TM MD

Search Reset

Найдено патентов - **9**, МНН (комбинаций) - **1** (по состоянию на **2025.10.27**)

PATENT	TITLE OF THE INVENTION	PATENT OWNER(S)
РЕГОРАФЕНИБ / REGORAFENIB		
EA010485	ПРОИЗВОДНОЕ N,N' -ДИФЕНИЛМОЧЕВИНЫ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ (ВАРИАНТЫ) И СПОСОБ ЛЕЧЕНИЯ И ПРЕДУПРЕЖДЕНИЯ ЗАБОЛЕВАНИЙ И СОСТОЯНИЙ С ЕГО ИСПОЛЬЗОВАНИЕМ (ВАРИАНТЫ) N,N-DIPHENYL UREA DERIVATIVE, PHARMACEUTICAL COMPOSITION (EMBODIMENTS) THEREOF, AND METHOD FOR THE TREATMENT AND PREVENTION OF DISEASES AND CONDITIONS USING IT (EMBODIMENTS)	БАЙЕР ХЕЛСКЕА ЭЛЭЛСИ (US) BAYER HEALTHCARE LLC (US)
EA027685	ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ С ПОКРЫТИЕМ, СОДЕРЖАЩАЯ РЕГОРАФЕНИБ COATED PHARMACEUTICAL COMPOSITION CONTAINING REGORAFENIB	БАЙЕР ХЕЛСКЕР ЛЛСи. (US) BAYER HEALTHCARE LLC (US)
BY16460	Моногидрат 4-[4-({[4-хлор-3-(трифторметил)фенил]карбамоил}амино)-3-фторфенокси]-N-метилпиридин-2-карбоксамида 4-[4-({[4-chloro-3-(trifluoromethyl) phenyl] carbamoyl } amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide monohydrate	БАЙЕР ХЕЛСКЕР ЛЛСи BAYER HEALTHCARE LLC
BY22494	Способ получения 4-{4-[({[4-хлор-3-(трифторметил)фенил]амино}-карбонил)амино]-3-фторфенокси}-N-метилпиридин-2-карбоксамида моногидрата Process for the preparation of 4-{4-[({[4-chloro-3-(trifluoromethyl) phenyl] amino }-carbonyl) amino]-3-fluorophenoxy }-N-methylpyridine-2-carboxamide monohydrate	БАЙЕР ХЕЛСКЕР ЛЛСИ BAYER HEALTHCARE LLC
BY23370	Смесь 4-{4-[({[4-хлор-3-(трифторметил)фенил]амино}карбонил)амино]-3-фторфенокси}-N-метилпиридин-2-карбоксамида, его моногидрата и одного или более анилиновых соединений A mixture of 4-{4-[({[4-chloro-3-(trifluoromethyl) phenyl] amino } carbonyl) amino]-3-fluorophenoxy }-N-methylpyridine-2-carboxamide, its monohydrate, and one or more aniline compounds	БАЙЕР ХЕЛСКЕР ЛЛСИ BAYER HEALTHCARE LLC
RU2466992	МОНОГИДРАТ 4-[4-({[4-ХЛОР -3(ТРИФТОРМЕТИЛ)ФЕНИЛ]КАРБАМОИЛ}АМИНО)-3-ФТОРФЕНОКСИ]-N-МЕТИЛПИРИДИН-2-КАРБОКСАМИДА MONOHYDRATE OF 4-[4-({[4-CHLORO -3 (TRIFLUOROMETHYL) PHENYL] CARBAMOYL } AMINO)-3-FLUOROPHENOXY]-N-METHYLPYRIDINE-2-CARBOXAMIDE	БАЙЕР ХЕЛСКЕР ЛЛСИ BAYER HEALTHCARE LLC

EURASIAN PHARMACEUTICAL REGISTRY

EAPO

INN (combination)
Enter INN

Patent Number
Enter patent number

Patent Owner(s)
Enter patent owner information

Title of the Invention
Enter the title of the invention

Patent status
Active

☐ EA ☐ AM ☐ AZ ☐ BY ☐ KG ☐ KZ ☑ RU ☐ TJ ☐ TM ☐ MD

Search | Reset

Найдено патентов - **53**, МНН (комбинаций) - **25** (по состоянию на **2025.10.27**)

PATENT	TITLE OF THE INVENTION	PATENT OWNER(S)
АПИКСАБАН / APIXABAN		
RU2345993	ЛАКТАМСОДЕРЖАЩЕЕ СОЕДИНЕНИЕ И ЕГО ПРОИЗВОДНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ ФАКТОРА Xa LACTAM-CONTAINING COMPOUND AND ITS DERIVATIVES AS Xa FACTOR INHIBITORS	БРИСТОЛ-МАЙЕРС СКВИББ ХОЛДИНГС АЙЕЛЕНД АНЛИМИТЕД КОМПАНИ BRISTOL-MYERS SQUIBB HOLDINGS IRELAND UNLIMITED COMPANY
АСЦИМИНИБ / ASCIMINIB		
RU2820241	ХИМИЧЕСКИЙ СПОСОБ CHEMICAL METHOD	НОВАРТИС АГ NOVARTIS AG
RU2836337	КРИСТАЛЛИЧЕСКИЕ ФОРМЫ N-[4-(ХЛОРДИФТОРМЕТОКСИ)ФЕНИЛ]-6-[(3R)-3-ГИДРОКСИПИРРОЛИДИН-1-ИЛ]-5-(1H-ПИРАЗОЛ-5-ИЛ)ПИРИДИН-3-КАРБОКСАМИДА CRYSTALLINE FORMS OF N-[4-(CHLORODIFLUOROMETHOXY)PHENYL]-6-[(3R)-3- HYDROXYPYRROLIDIN-1-YL]-5-(1H-PYRAZOL-5-YL)PYRIDINE-3-CARBOXAMIDE	НОВАРТИС АГ NOVARTIS AG
ВАЛСАРТАН + САКУБИТРИЛ / VALSARTAN + SACUBITRIL		
RU2334513	ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, ВКЛЮЧАЮЩИЕ ВАЛСАРТАН И ИНГИБИТОРЫ НЕЙТРАЛЬНОЙ ЭНДОПЕПТИДАЗЫ (NEP) PHARMACEUTICAL COMPOSITIONS INCLUDING VALSARTAN AND INHIBITORS OF NEUTRAL ENDOPEPTITAS (NEP)	НОВАРТИС АГ NOVARTIS AG
RU2459809	ФАРМАЦЕВТИЧЕСКИЕ КОМБИНАЦИИ АНТАГОНИСТА РЕЦЕПТОРА АНГИОТЕНЗИНА И ИНГИБИТОРА NEP PHARMACEUTICAL COMBINATIONS OF ANGIOTENSINE RECEPTOR ANTAGONIST AND NEP INHIBITOR	НОВАРТИС АГ NOVARTIS AG

PROSPECTS

Information contained in Pharmaceutical Register may be recognized as official certifying the protection of API on the territory of Member State

Mechanisms of recognition

- At *supra* national level
  - under an agreement concluded between Member State and EAPO
- At national level
  - amendments in national laws

Use of PharmRegister

- To enforce and protect the patent rights to API-related inventions
  - including through provisional measures under the national law of the Member State

- Determined particularly by the Member State
  - in issuing market authorization
  - in public procurements
  - in infringement litigations

EURASIAN
PATENT
OFFICE

THANK YOU!

Eurasian
Pharmaceutical
Register

EAPO
Web Site

EAPO-ONLINE
(RUS)